EDSA - The Buzz Show: Edesa Biotech (NASDAQ: EDSA) Clinical Study for Covid-19 Treatment

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients ”

Edesa Biotech, Inc.  (NASDAQ: EDSA) surged over 60% in premarket trading after the company announced positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate.

While the Phase 2 portion was primarily designed to refine patient stratification and statistical powering for the Phase 3 study, the DSMB concluded that “a clinically important efficacy signal” was detected and that the study has “met its objective.”

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS).

For more information, please visit: Edesa Biotech, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Edesa Biotech (NASDAQ: EDSA) Clinical Study for Covid-19 Treatment first appeared on Financial Buzz .

For further details see: